Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyldopa is a centrally acting antihypertensive small molecule used primarily to treat high blood pressure (hypertension), including as a preferred option during pregnancy[1][2][5]. It works by being metabolized in the brain to alpha-methylnorepinephrine, which acts as an agonist at presynaptic alpha-2 adrenergic receptors. This reduces central sympathetic outflow, leading to vasodilation and decreased peripheral vascular resistance without significantly affecting cardiac output[5][6][8]. Methyldopa is available in oral tablet and solution forms and is only available by prescription. Common side effects include drowsiness, headache, weakness, and fluid retention; serious risks include liver damage and blood disorders[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyldopa.